BioInvent International
25.11.2021 08:51:35 CET | ACCESS Newswire | Press release
LUND, SWEDEN / ACCESSWIRE / November 25, 2021 / BioInvent International (STO:BINV)
Lund, Sweden - November 25, 2021 - The members of the Nomination Committee for BioInvent International AB:s (publ) ("BioInvent") Annual General Meeting in 2022 have now been appointed.
The following representatives of BioInvent International AB's shareholders will be members of the Nomination Committee for the Annual General Meeting 2022:
- Laura Feinleib, appointed by Redmile Group, LLC
- Erik Esveld, appointed by van Herk Investments B.V.
- Vincent Ossipow, appointed by Omega Funds, LP
- Leonard Kruimer, Chairman of the Board
The Nomination Committee shall prepare proposals for the Annual General Meeting in 2022 regarding Chairman of the General Meeting, Chairman of the Board and other Board members, board remuneration shared among the Chairman and other Board members, possible compensation for committee work, and election of auditors and auditor's fees.
The Annual General Meeting will be held on April 28, 2022 in Lund, Sweden.
Proposals to the Nomination Committee can be sent to Stefan Ericsson, by mail: BioInvent International AB (publ).), SE-223 70 Lund or telephone: +46 (0)46-46 286 85 50 in good time before March 10, 2022
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
Tel: +46 46 286 85 50
Email. cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/674695/Nomination-Committee-Appointed-for-BioInvent-Internationals-Annual-General-Meeting-2022
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Flow Technology partners with BW Forsyth Partners to Meet Growing Demand for Biopharmaceutical Manufacturing7.9.2026 10:00:00 CEST | Press release
Investment supports Flow Technology's ability to help pharmaceutical and biotechnology manufacturers expand production and navigate increasingly complex manufacturing requirements CHARLEVILLE, IRELAND / ACCESS Newswire / September 7, 2026 / Flow Technology, a provider of engineered process systems and skid integration solutions serving the global life sciences industry, announced a partnership with BW Forsyth Partners that will support the company's continued expansion in the United States and Europe, and enhance its ability to serve the evolving needs of global pharmaceutical and biotechnology manufacturers. The partnership comes as pharmaceutical and biotechnology companies invest heavily in production capacity, advanced manufacturing technologies and domestic supply chains. Flow Technology's expertise in downstream purification, filtration and chromatography systems positions the company to support the increasingly sophisticated process infrastructure required to manufacture next-ge
LiberNovo Showcases Dynamic Ergonomic Seating at IFA 2026 and Supports Special Olympics New York4.9.2026 18:30:00 CEST | Press release
Maxis Series Brings More Space, Support and Choice to Big & Tall Users BERLIN, DE / ACCESS Newswire / September 4, 2026 / LiberNovo is exhibiting at IFA 2026 from September 4 to 8 at Messe Berlin, presenting its dynamic ergonomic seating range at Hall 7, Stand 7.2a-105. The Maxis Series leads the stand, alongside the LiberNovo Omni Pro and Omni SE. LiberNovo Omni Pro has also earned nominations in two IFA Innovation Awards categories: Best in Design and Best in Tech for Good & Accessibility. IFA is a leading event for consumer technology and home appliances, connecting brands, retailers, buyers and media. Its 2026 theme, "The future is now," highlights technology reshaping everyday life. As hybrid work, gaming and content creation extend sitting time, LiberNovo presents seating as an active support system rather than a static object. Maxis Series: Built for Bigger Builds Maxis was designed for taller, broader and heavier users rather than scaled up from a standard chair. Its 52 cm (20.
Suntex Enterprises Launches Ambitious $1 Billion+ North American Real Estate Development Initiative4.9.2026 13:30:00 CEST | Press release
Two major Alberta projects are projected to generate approximately $575 million in revenue as Suntex expands its integrated development, construction, and ownership platform throughout Canada and the United States. AUSTIN, TX / ACCESS Newswire / September 4, 2026 / Suntex Enterprises, Inc. (OTCID:SNTX) ("Suntex" or the "Company"), a dynamic operating and holding company dedicated to real estate development, construction, infrastructure, and land, proudly announces the signing of a Letter of Intent ("LOI") that advances a transformative multiyear real estate development partnership across North America. The LOI builds upon the Canadian development relationship unveiled by Suntex in July 2026 and lays the groundwork for a robust initial portfolio of large-scale development opportunities designed to drive substantial growth across the Company's expanding North American platform. The portfolio is anchored by Royal Links in Leduc, Alberta, and Meridian in Alberta, representing $575 million
Formerra Receives 2026 Eaton Supplier Excellence Award3.9.2026 16:45:00 CEST | Press release
Recognition places Formerra among several dozen honorees from a supplier network of more than 30,000. ROMEOVILLE, IL / ACCESS Newswire / September 3, 2026 / Formerra, a leader in performance materials distribution, was recognized for its partnership at Eaton's 2026 Global Supplier Conference & Excellence Awards, held Thursday, August 27 in Beachwood, Ohio. Formerra was one of only 30 suppliers recognized with Eaton's Supplier Excellence Award from among the company's global network of more than 30,000 supplier partners. Eaton grants the Supplier Excellence Award to suppliers that exceed expectations through exceptional performance, innovation, and contributions to growth. Formerra serves as Eaton's preferred plastics distribution partner, a role built through disciplined execution and engagement across Eaton's corporate organization and manufacturing sites. While the partnership began over 15 years ago in North America, it now extends into Asia, Europe, and the Middle East, where Forme
DistillerSR Joins European MedTech Consortium to Digitalize Medical Device and IVD Conformity Assessments3.9.2026 16:00:00 CEST | Press release
€4 million European-funded DIGICAP project brings together 19 organizations to replace document-based conformity assessments with machine-readable data. DistillerSR named one of five technology providers building the framework. OTTAWA, ON / ACCESS Newswire / September 3, 2026 / DistillerSR, the market leader in AI-enabled literature review automation and evidence management, today announced its participation in DIGICAP (DIGItalisation of the Conformity Assessment Process), a €4 million European initiative uniting 19 organizations across 12 EU countries to digitalize how medical devices and in vitro diagnostics are certified for the European market. The project is funded under Horizon Europe, the world's largest multinational research and innovation program, with a budget of €95.5 billion for the 2021-2027 period. DistillerSR is one of five regulatory technology providers selected to support the project, alongside Veeva, MEDDEVO, AUREVIA and Hardian Health. The company will work in the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom